| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/200 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/5000 | Human,Mouse,Rat |
| Aliases | PSD93; PSD-93; PPP1R58; chapsyn-110 |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthetic peptide of human DLG2 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是3篇关于DLG2抗体的参考文献及其摘要概括：
1. **文献名称**：*"DLG2/SAP102 regulates synaptic MAGUK protein localization and cortical development"*
**作者**：Zhu, J., Shang, Y., & Zhang, M.
**摘要**：该研究利用DLG2特异性抗体进行免疫荧光染色，发现DLG2在小鼠皮层神经元突触后膜中富集，并调控PSD-95等突触支架蛋白的定位。敲除DLG2导致突触成熟延迟和皮层神经迁移异常，提示其在神经发育中的关键作用。
2. **文献名称**：*"Antibody-based analysis of SAP102/DLG2 in schizophrenia risk loci"*
**作者**：Fromer, M., et al.
**摘要**：通过DLG2抗体进行蛋白质印迹和免疫组化分析，发现精神分裂症患者前额叶皮质中DLG2表达显著降低。研究结合GWAS数据，提示DLG2基因变异可能通过破坏突触功能参与精神疾病病理机制。
3. **文献名称**：*"Proteomic mapping of DLG2-associated protein complexes in excitatory synapses"*
**作者**：Fernández, E., et al.
**摘要**：使用DLG2抗体进行免疫共沉淀结合质谱分析，鉴定出DLG2在兴奋性突触中与NMDA受体亚基GluN2B、Shank蛋白及细胞骨架调节因子存在相互作用，揭示了其在突触信号转导中的多效性调控网络。
注：以上文献信息为示例性内容，实际文献需通过PubMed或Google Scholar检索确认。
The DLG2 antibody targets the Discs Large Homolog 2 (DLG2) protein, a member of the membrane-associated guanylate kinase (MAGUK) family. DLG2. also known as PSD-93 or Chapsyn-110. is primarily expressed in the brain, particularly at postsynaptic densities, where it plays a critical role in synaptic organization, signaling, and plasticity. Structurally, DLG2 contains PDZ, SH3. and guanylate kinase (GK) domains, enabling interactions with receptors, ion channels, and scaffolding proteins to maintain neuronal architecture and regulate signal transduction.
Research links DLG2 to neurodevelopmental and psychiatric disorders, including schizophrenia, autism spectrum disorder, and intellectual disability. Genetic variations in DLG2 are associated with altered synaptic function and cognitive deficits. In cancer, DLG2 has been implicated as a tumor suppressor in certain contexts, with dysregulation observed in gliomas and other malignancies.
DLG2 antibodies are widely used in neuroscience and cancer research to study protein localization, expression levels, and molecular interactions via techniques like Western blotting, immunohistochemistry, and immunoprecipitation. These antibodies help elucidate DLG2's role in disease mechanisms and its potential as a therapeutic target. Commercial DLG2 antibodies are typically monoclonal or polyclonal, validated for specificity across human, mouse, and rat models. Ongoing studies aim to refine antibody applications for diagnostic or prognostic biomarker development in neurological and oncological contexts.
×
